REGENERON PHARMACEUTICALS, INC. — 13F Holdings

2026 Q2  ·  3 Positions

2026 Q2 Portfolio Activity

In 2026 Q2, REGENERON PHARMACEUTICALS, INC. maintained a portfolio of 3 distinct positions. The most significant new addition was Parabilis Medicines, Inc., now representing 64.35% of the total fund value.
Position History hover any row below to update
Loading…
REGENERON PHARMACEUTICALS, INC. Tarrytown, NY Operating Company AUM $177M
Fund Overview SEC EDGAR
PCA Score Concentration Risk
Risk ENB
To Excel To CSV
Total Positions
3
Quarter
2026 Q2
Top Holding
N/A (64.4%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-3 of 3
Stock History Sector / Type Port % Prev % Rank / Prev Conviction
Freshness
Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
N/A
Parabilis Medic...
Unknown 64.35% — #1
Prev: #—
9.5
—
4,166,666 —
NEW
 4,166,666 $114,041,648 — 13F Filing 2026-06-30 2026-08-07
NTLA
Intellia Therap...
Healthcare 35.35% 99.14% #2 1
Prev: #1
6.5
—
no change no change
P
S
3,702,995 $62,654,675 2024 Q4 13F Filing 2026-06-30 2026-08-07
ACET
Adicet Bio, Inc...
Healthcare 0.30% 0.86% #3 1
Prev: #2
2.1
—
no change no change
P
S
60,511 $522,819 2024 Q4 13F Filing 2026-06-30 2026-08-07
Showing 1-3 of 3 holdings

Unlock Full REGENERON PHARMACEUTICALS, INC. Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Upgrade to PRO
Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics
Full history →